Spero Therapeutics (SPRO) Cash from Investing Activities (2016 - 2022)

Spero Therapeutics (SPRO) has 6 years of Cash from Investing Activities data on file, last reported at -$129000.0 in Q3 2022.

• For the quarter ending Q3 2022, Cash from Investing Activities fell 100.76% year-over-year to -$129000.0; the trailing twelve-month figure through Jun 2023 stood at -$129000.0 (down 100.47% YoY), and the FY2022 full-year result was $33.8 million, up 340.65% from the prior year.
• Cash from Investing Activities for Q3 2022 stood at -$129000.0, down from $50.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $50.0 million in Q2 2022 and bottomed at -$72.6 million in Q3 2018.
• The 5-year median for Cash from Investing Activities is $3.9 million (2020), against an average of -$88263.2.
• The widest annual swing landed in 2019, when Cash from Investing Activities soared 396.9%; it then slumped 869.5% in 2020.
• A 5-year view of Cash from Investing Activities shows it stood at $7.3 million in 2018, then plunged by 156.25% to -$4.1 million in 2019, then plunged by 869.5% to -$39.7 million in 2020, then surged by 41.43% to -$23.3 million in 2021, then surged by 99.45% to -$129000.0 in 2022.
• The last three Cash from Investing Activities figures came in at -$129000.0 (Q3 2022), $50.0 million (Q2 2022), and -$16.1 million (Q1 2022), per Business Quant data.

Peer Comparison